CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Thomas Yau(University of Hong Kong), J.W. Park(National Cancer Center), Richard S. Finn(University of California, Los Angeles), Ann‐Lii Cheng(National Taiwan University Hospital), Philippe Mathurin(Hôpital Claude Huriez), Julien Edeline(Centre Eugène Marquis), Masatoshi Kudo(Kindai University), Kwang‐Hyub Han(Yonsei University), James J. Harding(Memorial Sloan Kettering Cancer Center), Philippe Merle(Hôpital de la Croix-Rousse), Olivier Rosmorduc(Sorbonne Université), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), E. Schott(Helios Klinikum Emil von Behring), Su Pin Choo(National Cancer Centre Singapore), Robin Kate Kelley(University of California, San Francisco), Damir Begic(Bristol-Myers Squibb (United States)), G. Chen(Bristol-Myers Squibb (United States)), Jaclyn Neely(Bristol-Myers Squibb (United States)), Jeffrey Anderson(Bristol-Myers Squibb (United States)), Bruno Sangro(Centro de Investigación Biomédica en Red)
Cited by 646Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis